fda warning letter compounding semaglutide october 2025 letters alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA warns consumers not to – FDA Drug Recalls and Warnings:

small top-up given if needed

Here's what the program covers, who qualifies, and how to use it if you or a family member on Medicare is interested

Ohio to end GLP-1 drug weight loss coverage for state workers COLUMBUS, Ohio (WSYX) The Ohio Department of Administrative Services announced that coverage for GLP-1 drugs for weight loss, including Ozempic and Mounjaro, will end for state employees on July 1, 2025

Key Takeaways Nutrition strategies can complement GLP-1 medications by improving adherence, reducing hunger, and supporting more sustainable weight loss outcomes

Arrae Sleep calms your nervous system and supports your body's natural sleep cycle no melatonin, no sedative hangover